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ABSTRACT 
 
To study associations of genetic polymorphisms of cytokines with the risk of preeclampsia 
development. The study involved 250 pregnant women with preeclampsia and 245 women with a 
physiological pregnancy. All pregnant women with preeclampsia and women of the control group were typed 
four genetic polymorphisms of cytokines: tumor necrosis factor α (-308G/A TNFα, rs1800629), lymphotoxin α 
(+250A/G Ltα, rs909253), tumor necrosis factor receptor 1 (+36A/G TNFR1, rs767455), interferon-inducible T-
cell alpha chemoattractant (A/G I-TAC, rs 4512021). The combination of alleles +250A Ltα and G I-TAC (rs 
4512021) with genotype +36GG TNFR1 was observed in 13.38% of pregnant women with PE, whereas the 
frequency in the control group was 20.00% (OR=0.62, 95% CI 0.38-1.00, p=0.03). The results indicate the 
connection of genetic cytokine polymorphisms with the risk of preeclampsia development in the population of 
the Central Black Earth Region of Russia: the combination of genetic variants +250A Ltα, G I-TAC (rs4512021), 
+36GG TNFR1 has a protective effect on the development of preeclampsia (OR=0.62). 
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INTRODUCTION 
 
Preeclampsia (PE) is a complication of pregnancy, characterized by the development of endothelial 
dysfunction, multiple organ failure, disruption of coagulation and anticoagulation systems, microcirculation, 
metabolic processes, immune response (Eiland, Nzerue, 2012). 
 
According to the world literature and WHO, the incidence of preeclampsia is 2-8% (Duley, 2009; 
Abalos et al., 2014). Preeclampsia remains an important cause of maternal, perinatal and neonatal morbidity 
and mortality (Abalos et al., 2014; Vogel et al., 2014).  
 
Severe preeclampsia and eclampsia causes the risk of complications such as hemorrhages and 
cerebral edema, placental abruption, disseminated intravascular coagulation syndrome, massive obstetric 
hemorrhages, HELLP syndrome, hemorrhage and rupture of the liver capsule, pulmonary edema, adult 
respiratory distress syndrome, acute renal and hepatic insufficiency (Abalos et al., 2014).  
 
According to a number of studies, this complication of pregnancy has a multifactorial nature (Pinheiro, 
2015; Zhou et al., 2016; Reshetnikov et al., 2017). Local gene networks of preeclampsia include endothelial 
dysfunction genes, vascular reaction genes, growth factor and cytokine genes, major histocompatibility genes, 
etc. (Goddard et al., 2007; Johnson et al., 2012; Bell et al., 2013; Zhao et al., 2013; Alpoim et al., 2014; Mistry 
et al., 2015; Reshetnikov et al., 2017). 
 
It should be noted that the results of molecular genetic studies of preeclampsia obtained by authors 
in different populations are often contradictory (Johnson et al., 2012; Ozkan et al., 2015; Wan et al., 2016; 
Zhao et al., 2016; Reshetnikov et al., 2017; Reshetnikov et al., 2018).  
 
MATERIALS AND METHODS 
 
Object of study 
 
To conduct the study, a sample of 495 women was formed, which included 250 pregnant women with 
preeclampsia and 245 women with a physiological pregnancy. Samples of pregnant women with preeclampsia 
and control women included individuals of Russian nationality, born in the Central Black Earth Region of the 
Russian Federation and not related to each other. The average age of patients with preeclampsia is 31.2±7.5 
years, control - 30.2±6.3 years (p>0.05). The group of patients with preeclampsia included individuals 
diagnosed with preeclampsia confirmed by clinical and clinical-laboratory examination. Preeclampsia was 
determined by the presence of hypertension, accompanied by proteinuria, as defined by a 24 h urine protein 
excretion more than 300 mg (ACOG Committee on Practice Bulletins-Obstetrics, 2002). 
 
The control group included women with a physiological pregnancy. Examination of pregnant women 
was conducted in the Perinatal Center of St. Joasaph Belgorod Regional Clinical Hospital. 
 
All patients with preeclampsia and individuals of the control group were typed four genetic 
polymorphisms of cytokines: tumor necrosis factor α (-308G/A TNFα, rs1800629), lymphotoxin α (+250A/G 
Ltα, rs909253), tumor necrosis factor receptor 1 (+36A/G TNFR1, rs767455), interferon-inducible T-cell alpha 
chemoattractant (A/G I-TAC, rs 4512021).   
 
Molecular and genetic methods  
 
 A genomic DNA was isolated from peripheral blood by the method of standard phenol-chloroform 
extraction from frozen venous blood.  
 
DNA markers genotyping was produced by the method of TaqMan probes detection according to RFU 
values (relative fluorescence unit) of each probe on the thermocycler IQ5 with detecting system in real time. 
Bio-Rad IQ5-Standart Edition program was used for the alleles discrimination.  
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Statistical methods  
 
Statistical processing of data was carried out using STATISTICA for Windows 6.0 and Microsoft Excel 
2007 software packages. To verify the compliance of the observed distribution of genotypes with the expected 
one, based on Hardy-Weinberg equilibrium, we used 2 test. Associations of alleles and genotypes of the 
studied DNA markers with the formation of preeclampsia were evaluated by analyzing the 2×2 contingency 
tables with the calculation of the χ2 criterion with the Yates correction for continuity and the odds ratio (OR) 
with a 95% confidence interval. Analysis of the role of combinations of genetic variants of cytokines in the 
occurrence of preeclampsia was carried out with the APSampler software, using the Markov chain Monte Carlo 
method and Bayesian nonparametric statistics (Favorov et al., 2005).  
 
RESULTS AND DISCUSSION 
 
The study of the concentrations of allele frequencies and genotypes of polymorphic markers -308G/A 
TNFα (rs1800629), +250A/G Ltα (rs909253), +36A/G TNFR1 (rs767455) in the group of pregnant women with 
preeclampsia and in the control group showed no statistically significant differences (Table 1). 
 
Table 1: Frequency of genetic variants of cytokines in pregnant women with preeclampsia and without 
preeclampsia, (%) 
 
Locus 
Alleles, 
Genotypes 
Pregnant women 
without 
preeclampsia 
(n=245) 
Pregnant women 
with preeclampsia 
(n=250) 
ОR (95% СI) 
χ2, p 
ni % ni % 
-308G/A TNFα 
(rs1800629) 
-308G 436 89.02 438 88.66 
1.03 (0.69-1.57) 
χ2=0.01. p=0.93 
-308A 54 10.98 56 11.34 
-308GG 192 78.37 195 78.95 
1.03 (0.65-1.63) 
χ2=0.01. p=0.96 
-308GA 52 21.14 48 19.43 
0.90(0.56-1.42) 
χ2=0.15. p=0.70 
-308AA 1 0.40 4 1.62 
4.02 (0.42-96.74) 
χ2=0.79. p=0.37 
+250A/G Ltα 
(rs909253) 
+250A 364 74.59 371 74.80 
1.00 (0.74-1.35) 
χ2=0.01. p=1.00 
+250G 124 25.41 125 25.20 
+250AA 132 54.10 138 56.65 
1.06 (0.73-1.54) 
χ2=0.07. p=0.78 
+250AG 100 41.00 94 37.90 
0.88 (0.60-1.28) 
χ2=0.37. p=0.54 
+250GG 12 4.90 16 6.45 
1.33 (0.58-3.08) 
χ2=0.29. p=0.59 
+36A/G 
TNFR1 (rs767455) 
+36A 242 48.40 246 50.83 
1.10 (0.85-1.43) 
χ2=0.49.p=0.49 
+36G 258 51.60 238 49.17 
+36AA 59 23.60 63 26.03 
0.87 (0.57-1.35) 
χ2=0.27.p=0.60 
+36AG 124 49.60 120 49.59 
1.00 (0.69-1.45) 
χ2=0.01. p=1.00 
+36GG 67 26.80 59 24.38 
0.90 (0.59-1.38) 
χ2=0.16. p=0.69 
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A/G I-TAC (rs4512021) 
G 213 44.01 208 41.60 
1.10 (0.85-1.43) 
χ2=0.49. p=0.49 
A 271 55.99 292 58.40 
AA 78 32.23 81 32.40 
1.01(0.68-1.50) 
χ2 = 0.01. p=1.00 
GA 115 47.52 130 52.00 
1.20 (0.83-1.73) 
χ2 = 0.82. p=0.37 
GG 49 20.25 39 16.00 
0.73 (0.45-1.19) 
χ2 = 1.51. p=0.22 
 
The role of combinations of the cytokine genes in the formation of preeclampsia was studied with the 
help of bioinformational methods. As a result of the integrated analysis of the carriage of the combinations of 
alleles and genotypes of the cytokine genes studied, significant differences were found between pregnant 
women with preeclampsia and the control group. Thus, the combination of alleles +250A Ltα and G I-TAC (rs 
4512021) with +36GG TNFR1 genotype is observed in 13.38% of pregnant women with preeclampsia, whereas 
in the control group it was diagnosed in 20.00% (p=0.03). This combination protects from the development of 
preeclampsia (OR=0.62 .95% CI 0.38-1.00).  
 
The results of the study indicate the association of combinations of alleles and genotypes of 
polymorphic loci +250A/G Ltα (rs909253), +36A/G TNFR1 (rs767455), A/G I-TAC (rs4512021) with a reduced 
risk of preeclampsia. 
 
Our data agree with the literature on the medical and biological significance of cytokines in the body. 
Interferon-inducible T-cell alpha chemoattractant plays a fundamental role in maintaining homeostasis, the 
functioning of the immune system, affecting central nervous system cells, as well as endothelial cells involved 
in angiogenesis (Antoshina et al, 2005, Lockwood et al, 2013). According to Hirota et al. (2006), I-TAC has a 
positive proliferative effect on endothelial endometrial cells, which underlies the formation of preeclampsia 
(Lockwood et al, 2013). The  tumor necrosis factor receptor 1 controls an acute inflammatory response, 
accumulates in most cells, and stabilizes circulating TNF, increasing the half-life of this cytokine, consistent 
with literature data on the pathogenetic mechanisms of development of preeclampsia (Chan et al., 2000; 
Paludan et al., 2001). Lymphotoxin α influences the activity of fibroblasts, takes part in the metabolism of 
glucose, initiates the production of stress hormones, plays an important role in apoptosis processes (Ketlinskiy 
et al., 2008; Gallitano et al., 2016). Lymphotoxin α is produced in the early stages of vascular inflammatory 
processes and activates adhesion molecules and cytokines (RANTES, IP-10, MCP-1, BLC, SLC, ELC) secreted by 
endothelial cells (Asselbergs et al., 2007). These pathogenetic mechanisms are important in the development 
of preeclampsia (Steegers et al., 2010; Hartgill et al, 2013; Kartik, 2010). 
 
  The results of other studies on the search for associations of genetic polymorphisms of cytokines with 
a risk of preeclampsia development turned out to be conflicting. 
 
  A number of studies in the Slovak, Iranian and Chinese, North American populations have identified 
associations of α-308G/A TNFα polymorphism with the risk of developing preeclampsia (Harmon et al., 2014, 
Zubor et al., 2014; Tavakkol Afshari et al., 2016; Zhou et al., 2016). 
 
  Other researchers have not revealed such associations (Lachmeijer et al., 2001; Pissetti et al., 2015). 
 
The discrepancy between the results obtained in various studies can be related to differences in the 
ethnic and, respectively, the genetic background of the populations under study. 
 
CONCLUSION 
 
Thus, the results obtained indicate the involvement of the genetic polymorphisms +250A/G Ltα 
(rs909253), +36A/G TNFR1 (rs767455), A/G I-TAC (rs 4512021) in susceptibility to the development of 
preeclampsia in the population of the Central Black Earth Region of Russia: a combination of genetic variants 
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+250A Ltα, G I-TAC (rs 4512021), +36GG TNFR1 has a protective effect on the development of preeclampsia 
(OR=0.62). 
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